GC Biopharma's Varicella Vaccine Strain MAV/06 Gains WHO Recognition
GC Biopharma, a leading biopharmaceutical firm, proudly announces that its unique varicella vaccine strain, MAV/06, is now officially recognized by the World Health Organization (WHO) as a standard strain for varicella vaccination. This recognition, highlighted in the recent WHO Position Paper, signifies a substantial step forward for global immunization initiatives.
Implications of WHO Inclusion for MAV/06
The WHO Position Paper serves as critical guidance for immunization policy around the globe, shaped by the Strategic Advisory Group of Experts on Immunization (SAGE). The validation of MAV/06 provides a solid foundation for its incorporation into nationwide immunization programs.
For GC Biopharma, this endorsement not only legitimizes the quality of its vaccine, branded as BARYCELA Inj., but also aligns it with the more established Oka strain-based vaccines. This alignment allows BARYCELA Inj. to be used interchangeably with existing varicella vaccines within routine two-dose immunization schedules.
A Stronger Global Vaccine Supply Chain
This endorsement from the WHO enhances the robustness of the global vaccine supply chain. By endorsing the interchangeability of both MAV/06 and Oka strains, the risk of supply shortages can be minimized. This is a significant development in improving vaccination continuity across various markets.
BARYCELA Inj.: A Trusted Vaccine in Global Markets
GC Biopharma has been reliably supplying BARYCELA Inj. through organizations like the Pan American Health Organization (PAHO). With the recent WHO recognition, it is poised to strengthen its foothold in global procurement markets, ensuring that its high-quality varicella vaccine remains accessible.
Clinical Assurance of Safety and Efficacy
The MAV/06 strain's immunogenicity and safety have been thoroughly validated through a Phase 3 clinical trial of BARYCELA Inj., published in a respected peer-reviewed journal. The findings highlighted a robust immune response and an encouraging safety profile, which supports its use in national vaccination programs.
GC Biopharma's Commitment to Global Health
In a statement, Jaewoo Lee, Head of Regulatory Science & Product Development at GC Biopharma, expressed pride in this milestone achievement. He remarked, "The inclusion of MAV/06 in the WHO Position Paper marks a significant milestone in strengthening global varicella vaccine supply. With validated manufacturing capabilities and a strong track record of international supply, we're committed to supporting global immunization efforts with reliable access to high-quality vaccines."
A Legacy of Innovation in Vaccine Development
Having developed the MAV/06 strain in-house in 1993, GC Biopharma has utilized it in various products, including Suduvax and BARYCELA Inj., aiding in vaccination efforts for nearly three decades. Their experience and commitment to innovation continue to underpin their efforts in the field of biopharmaceuticals.
About GC Biopharma
GC Biopharma, previously known as Green Cross Corporation, is a biopharmaceutical company with its headquarters in Yong-in, South Korea. With over 50 years of heritage in the development and manufacturing of plasma derivatives and vaccines, the company is now expanding its reach, marked by the successful entry of their Alyglo product in the U.S. market.
The company believes in addressing future healthcare demands through continuous innovation, focusing on specialized R&D in protein engineering, mRNAs, and lipid nanoparticle drug delivery systems. This forward-thinking approach aims to offer effective therapeutics for rare diseases and areas within immunology and inflammation.
Frequently Asked Questions
What is the significance of MAV/06 being recognized by the WHO?
The recognition by the WHO establishes MAV/06 as a standard varicella vaccine strain, ensuring its inclusion in global immunization efforts.
How does the interchangeability of MAV/06 and Oka strains help?
Interchangeability helps maintain vaccine supply and allows for consistent vaccination strategies across various locations, minimizing potential shortages.
What are the benefits of BARYCELA Inj.?
BARYCELA Inj. has demonstrated strong immune responses and a favorable safety profile, making it a validated option for national immunization programs.
How long has GC Biopharma been in the vaccine industry?
GC Biopharma has a legacy of over 50 years in developing and manufacturing vaccines and plasma derivatives, contributing significantly to healthcare.
What future innovations can we expect from GC Biopharma?
GC Biopharma is focused on advancing its R&D capabilities to develop new therapeutics for rare diseases and improve vaccination strategies.
